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ABSTRACT
Deregulated mRNA translation has been implicated in disease development and in 
part is controlled by a eukaryotic initiation complex eIF4F (composed of eIF4E, eIF4G 
and eIF4A). We demonstrate here that the cap bound fraction from lymphoma cells 
was enriched with eIF4G and eIF4E indicating that lymphoma cells exist in an activated 
translational state. Moreover, 77% (110/142) of diffuse large B cell lymphoma tumors 
expressed eIF4E and this was associated with an inferior event free survival. Over-
expression of wild-type eIF4E (eIF4EWT) but not cap-mutant eIF4E (eIF4Ecap mutant) 
increased the activation of the eIF4F complex. Treatment with the active -site dual 
mTOR inhibitor CC214-1 reduced the level of the eIF4F complex by decreasing the 
cap bound fraction of eIF4G and increasing the levels of 4E-BP1. CC214-1 inhibited 
both the cap dependent and global protein translation. CC214-1 inhibited c-Myc, 
and cyclin D3 translation by decreasing polysomal fractions from lymphoma cells. 
Inhibition of eIF4E with shRNA further decreased the CC214-1 induced inhibition of 
the eIF4F complex, c-Myc, cyclin D3 translation, and colony formation. These studies 
demonstrate that the eIF4F complex is deregulated in aggressive lymphoma and that 
dual mTOR therapy has therapeutic potential in these patients.
INTRODUCTION
Non-Hodgkin lymphoma (NHL) is the 7th most 
common cause of cancer in the USA with diffuse large 
B-cell lymphoma (DLBCL) being the most common 
type in the US.[1] With standard RCHOP therapy 
approximately 60% of patients are cured; however, 40% 
of patients relapse and die of disease. New treatments are 
needed that target the specific signal pathways that are 
activated in lymphoma cells to enhance the initial response 
and prevent relapse. Recent reviews have described the 
potential importance of therapies that target protein 
translation.[2, 3] The translation of mRNA to protein 
is controlled by the eIF4F complex, a critical regulator 
of cap-dependent translation in eukaryotes. The eIF4F 
complex contains a translation initiation factor 4E (eIF4E), 
a scaffolding protein eIF4G, and the RNA helicase eIF4A. 
eIF4E is the cap-binding factor and its overexpression in 
solid tumor cells is associated with higher rates of cancer 
recurrence and cancer-related death.[4, 5] Various studies 
have demonstrated the overexpression of eIF4E in solid 
malignancies including esophageal cancer [6] and breast 
cancer;[7] however, there are currently no available FDA-
approved anti-cancer agents that directly target eIF4E.
eIF4E is controlled by 4E-binding proteins (4E-BPs) 
that are one of the important downstream targets of the 
mTOR pathway.[8] Hyper-phosphorylated 4E-BPs bind 
weakly to eIF4E allowing eIF4E to bind with eIF4G 
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and activate mRNA translation. It has been previously 
demonstrated that targeting 4E-BP1 phosphorylation 
using inhibitors of mTORC1 such as rapamycin analogues 
results in important but modest clinical responses.[9, 10] 
In vitro studies have attributed this partial and transient 
response to rapalogs to additional changes that occur, 
including high expression of mTORC2 and subsequent 
Akt and eIF4E phosphorylation.[11] To improve on the 
clinical results with single-agent mTORC1 inhibitors, 
combination therapies and dual mTOR inhibitors that 
target both mTORC1 and mTORC2 have been developed. 
These types of inhibitors compete with ATP in the 
catalytic site of mTOR, inhibiting the function of both 
mTORC1 and mTORC2 and blocking the feedback Akt 
and eIF4E activation.[12] We recently demonstrated that 
the cytotoxic and antiproliferative effects of dual mTOR 
inhibition were more effective than rapamycin at inhibiting 
malignant cell proliferation and inducing apoptosis.[13] 
The present study was designed to comprehensively 
evaluate the role of the eIF4F complex in aggressive 
lymphoma cell growth and learn if dual mTOR inhibitor 
could inhibit eIF4F complex mediated mRNA translation.
RESULTS
Integrity of the translation initiation complex 
eIF4F in lymphoma cells
We assessed the formation of the active eIF4F 
(m7GTP-eIF4E-eIF4G) translation initiation complex by 
a pull down assay using an agarose-immobilized m7GTP 
cap analog to capture eIF4E and its binding partners eIF4G 
and eIF4A in MCL cell line cells. The relative amount of 
captured eIF4G or eIF4A serves as an indicator of the 
integrity of the eIF4F translation complex. Cell lysates 
from Jeko, Mino, Granta, JVM2 and CD19+ normal 
B cells were incubated with m7GTP and analyzed by 
immunoblotting for the level of eIF4A and eIF4G. Our data 
demonstrate that the cap-bound fraction from normal B 
cells contained very little eIF4G and eIF4A. However, all 
the MCL cell lysates were enriched with eIF4G, eIF4E and 
eIF4A (Figure 1A). In order to determine the association 
of eIF4E with eIF4G, we repeated this experiment by 
pulling down eIF4G from the cell lysates of MCL cell 
lines and demonstrated that the immunoprecipitates of 
eIF4G fraction in MCL cell lysates were indeed enriched 
compared to normal B cells and IgG control (Supplemental 
Figure 1A). A pull down assay using eIF4E antibody 
demonstrated that immunoprecipitates of the eIF4E 
fraction were enriched in malignant B cells, suggesting 
reciprocal binding between eIF4G and eIF4E in MCL cells 
(Supplemental Figure 1B). Overall, these data demonstrate 
that the cap bound fraction from lymphoma cells was 
enriched with eIF4G, eIF4E and eIF4A, demonstrating 
that aggressive lymphoma B cells exist in a translationally 
activated state.
Effect of eIF4E depletion or overexpression 
on the eIF4F complex, cell growth and global 
protein translation
To further explore if the alterations in eIF4E 
availability determine the integrity of the eIF4F complex, 
we depleted eIF4E through shRNA and performed a cap 
affinity assay to assess the effect on the eIF4F complex. 
HEK293eIF4E/shRNA and HEK293con shRNA stable cells were 
immunoprecipitated with m7GTP beads and immunoblotted 
with eIF4G, 4E-BP1 and eIF4E antibodies. eIF4E inhibition 
reduced the association of eIF4G and 4E-BP1 without 
affecting whole cell lysate (10% input) (Figure 1B).
On the other hand, ectopic expression of eIF4E 
increased the binding of eIF4G and 4E-BP1 to cap in wild 
type (HEK293eIF4E/WT), but not in cap mutant (HEK293cap mutant) 
cells (Figure 1C). Surprisingly, wild type-eIF4E (eIF4E WT) 
was not able to increase the global protein translation (Data 
not shown). Colony formation in HEK293eIF4E/shRNA was 
significantly reduced and a 70% reduction was observed in 
the eIF4E-depleted cells (Figure 1D).
Mechanism of overactivation of translation 
initiation complex eIF4F complex
Formation of the cap dependent translation 
complex is dependent upon several factors such as 
availability of eIF4E due to PI3K/mTOR pathway 
activation, hyperphosphorylation of 4E-BP1, and eIF4E 
hyperphosphorylation. We sought to determine which 
factor(s) is responsible for the activated eIF4F complex in 
aggressive lymphoma.
We first examined whether there was evidence for 
eIF4E expression in untreated DLBCL tumor samples using 
a DLBCL TMA for IHC. The expression of eIF4E was 
assessed semi-quantitatively as follows; negative (< 10% of 
cells eIF4E positive) or positive (>10% tumor cells eIF4E 
positive). Overall, 77% (110/142) patient samples were eIF4E 
positive (Figure 2A). The eIF4E expression frequencies 
were similar for germinal center B (GCB) and activated B 
cell (ABC) tumors (Figure 2A). eIF4E overexpression was 
significantly associated with stages III and IV of Ann Arbor 
staging system (Table 1) and with an inferior EFS (p-value = 
0.12) (Figure 2B). eIF4E expression predicted inferior EFS 
both in patients with GCB (p-value = 0.16) (Figure 2C) or 
ABC (p-value = 0.22) tumor subtypes (Figure 2D).
Phosphorylated 4E-BP1 dissociates from eIF4E and 
contributes to the deregulation of eIF4F complex. Next, 
we assessed the constitutive phosphorylation status of p4E-
BP1Thr37/46, p4E-BP1Thr70 and p4E-BP1ser65 in normal B cells 
compared to MCL (Jeko, Mino, Granta and JVM2) cell lines. 
All four MCL cell lines over-expressed hyper-phosphorylated 
4E-BP1 at all the 3 sites; however, normal B cells have hypo-
phosphorylated 4E-BP1 (Supplemental Figure 2). Overall, 
these data suggest that high levels of eIF4E along with hyper-
phosphorylated 4E-BP1 exist in the lymphoma cells and 
contribute in the formation of active eIF4F complex.
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Figure 1: Integrity of eIF4F complex in normal B cells and lymphoma cells. (A) In vitro cap affinity assay was performed in 4 
MCL cell lines (as indicated in the figure) and CD19+ normal B cells and western blotting was performed using eIF4G, eIF4A and eIF4E 
antibodies. (B) Effect of eIF4E inhibition on eIF4F complex integrity was assessed in the lysates from stably transfected HEK293eIF4E/KO 
and HEK293control shRNA cells by the cap affinity assay. The experiment was performed in triplicate with similar results (C) In vitro cap affinity 
assay in HEK293 cells after transient overexpression of eIF4EWT and eIF4Ecap mutant. The experiment was performed in triplicate. (D) Colony-
forming assay was performed in stably transfected HEK293eIF4E/KO and HEK293control shRNA cells. Bars represent mean ± SD from 3 replicates. 
The experiment was performed in triplicate.
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Active site dual mTORC1/mTORC2 inhibitor 
CC214-1 blocks the eIF4F complex and cap 
dependent protein translation
Since there is currently no drug that can directly 
inhibit the deregulated eIF4F complex in cancer cells, 
we assessed the effect of the next generation dual mTOR 
inhibitor CC214-1 on the translation initiation complex 
downstream of mTOR. We performed a cap affinity 
assay in Jeko and Mino MCL cells treated with CC214-1. 
CC214-1 caused a dose dependent inhibition in the 
association of eIF4G and eIF4A with eIF4E in both Jeko 
and Mino cells without much effect on the global quantity 
of these proteins (Figure 3A). Further evidence that 
CC214-1 was inhibiting the eIF4F complex formation 
was the increase in eIF4E bound 4E-BP1 after CC214-1 
Figure 2: Expression of eIF4E in DLBCL subtypes. (A) Results of eIF4E IHC staining in all DLBCL and GCB and ABC DLBCL 
subtypes. (B) A Kaplan-Meier (KM) curve for EFS in patients with DLBCL based on the expression of eIF4E is shown. (C–D) KM survival 
curves for GCB (C) and ABC (D) DLBCL subtypes.
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treatment of Jeko and Mino cells. Total levels of 4E-BP1 
in the 10% input of CC214-1 treated immunoprecipitates 
were decreased (Figure 3A). Rapamycin, an mTORC1 
inhibitor failed to alter the binding of eIF4G and 4E-BP1 
to cap in Mino cells (Supplemental Figure 3A). We, then, 
evaluated the consequences of CC214-1 treatment on the 
4E-BP1 phosphorylation in MCL cell lines. We observed a 
dose dependent decrease in the hyper-phosphorylated form 
of 4E-BP1 in response to CC214-1 but not with mTORC1 
inhibitor at the given concentration. This effect was observed 
in multiple 4E-BP1 phosphorylation sites including 
4E-BP1 at serine 65 in Jeko cells (Supplemental Figure 3B). 
However, both CC214-1 and mTORC1 inhibitor inhibited 
the S6 ribosomal protein phosphorylation. CC214-1 
inhibited global protein translation in both Jeko and Mino 
cells (Supplemental Figure 4).
Table 1: Characteristics of the 142 patients with untreated diffuse large B-cell lymphoma used for 
eIF4E immunohistochemistry
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Effect of CC214-1 on the cap-dependent translation 
was examined using bicistronic plasmids. In this plasmid, 
renilla luciferase gene represents cap-dependent protein 
translation, and firefly luciferase gene control cap-
independent translation (pRF). CC214-1 inhibited the cap-
dependent translation in a dose dependent manner with 
limited effect on the cap-independent translation as shown 
by luciferase assay (Figure 3B).
The effect of CC214-1 on lymphoma cell survival was 
first evaluated in MCL cell lines such as Mino, Jeko, JVM2 
and Granta. CC214-1 treatment produced a dose dependent 
inhibition of survival in all the 4 MCL cell lines tested 
(Figure 3C). In order to overcome any differences regarding 
microenvironment and growth rate between MCL cell 
lines and patient samples, we treated malignant cells from 
4 different MCL patients with CC214-1 in-vitro. Similar to 
the cell lines, CC214-1 treatment caused inhibition of patient 
tumor cell survival (Figure 3D).
Effect of CC214-1 on translation of eIF4E 
targets
Long, highly structured 5′-UTRs are typical of 
proto-oncogene mRNAs such as c-Myc, Mcl-1 and 
Cyclin D3 and considered eIF4E sensitive.[3, 14] To 
evaluate the effects of treatment with CC214-1 on the 
transcription of eIF4E known targets, we performed 
qualitative RT-PCR using specific primers for cyclin 
D3, Mcl-1 and c-Myc. CC214-1 did not inhibit the 
transcription of cyclin D3, Mcl-1 and c-Myc mRNA in 
Jeko and Granta cells (Figure 4A). However, CC214-1 
was able to suppress c-Myc and cyclin D3 protein level 
in a dose dependent manner. Suppression of Mcl-1 was 
detectable only after treatment with higher concentrations 
of CC214-1 (Figure 4B).
Next, we assessed the effect of the inhibition of 
eIF4E on the response to CC214-1 on c-Myc, Mcl-1 
and cyclin D3 protein level. Our data demonstrate that 
eIF4E inhibition increased the sensitivity of CC214-1 to 
inhibit c-Myc, Mcl-1 and cyclin D3 protein levels at 2 
μM concentration. (Figure 4C). Moreover, 4 μM CC214-1 
still affected sensitivity of Mcl-1 and Cyclin D3 to eIF4E 
inhibition; however, we have not observed the same 
response in c-Myc protein (Figure 4C).
CC214-1 reduces c-Myc, Mcl-1 and cyclin D3 
translation by inhibiting polysomal RNA
Polysomes are groups of actively translating 
ribosomes that are held together by a single mRNA 
transcript. Polysome profiling was carried out in Jeko 
and Mino cells as described in the Methods section. 
We investigated the mechanism of the translation 
inhibition function by CC214-1 using sucrose density 
gradient centrifugation. CC214-1 caused a decrease 
in the RNA absorbance at the heavier gradients 
suggesting polysome inhibition (Figure 5A) in Jeko 
and Mino cells.
Polysomal mRNA levels of c-Myc, Mcl-1 and 
cyclin D3 were assessed in response to CC214-1 in the 
pooled monosomal and polysomal fractions. Indeed, in 
cells treated with CC214-1 there was a reduction of c-Myc 
(Figure 5B), cyclin D3 (Figure 5C) and Mcl-1 (Figure 5D) 
mRNAs only in the polysomal fractions in MCL cells. 
These data suggest that the dual mTOR inhibitor CC214-
1 interferes with translation process by inhibiting the 
function of actively translating ribosomes.
Effect of increased or decreased eIF4E 
availability on CC214-1 mediated effect on eIF4F 
complex
eIF4E levels have been found to be elevated in 
several types of cancer.[15–18] To elucidate the role of 
eIF4E availability in the response to CC214-1 on eIF4F 
complex, eIF4E was knocked down and then the cells 
were treated with CC214-1. CC214-1 was able to inhibit 
the binding of eIF4E and eIF4G to cap in both eIF4E 
shRNA as well as in the control shRNA cells; however, 
inhibition was slightly more in the eIF4E depleted cells 
(Figure 6A, left panel). Next, we sought to determine the 
CC214-1 effect on eIF4F complex integrity while eIF4E is 
overexpressed. Wild type eIF4E was transiently expressed 
and assays for cap affinity, proliferation, and apoptosis 
were performed. CC214-1 suppressed the binding of 
eIF4G to cap in HEK293cap mutant and HEK293PCDNA3.1 cells. 
CC214-1 was able to inhibit binding of eIF4G to cap in 
cells over-expressing wild type-eIF4E but the binding 
was less inhibited as compared to HEK293PCDNA3.1 and 
HEK293cap mutant (Figure 6A, right panel).
Furthermore, the assay revealed a 72% inhibition in 
the cell proliferation in the plasmid alone cells as compared 
to untreated cells. However only 39% inhibition was 
observed in the proliferation in the eIF4E overexpressing 
cells as compared to untreated cells (Figure 6B, panel left). 
To further confirm the effect of high eIF4E availability on 
cell survival after treatment with CC214-1, flow cytometry 
was performed. HEK293PCDNA3.1 cells showed 26% 
reduction of survival in plasmid alone cells as compared 
to the untreated control, however eIF4E overexpressing 
cells showed only 7% inhibition in survival as compared 
to the untreated control (Figure 6B, panel right).
In eIF4E-shRNA cells, treatment with CC214-1 was 
able to significantly inhibit colony formation (70%) as 
compared to control shRNA cells (50%) (Figure 6C). To 
evaluate the effect of c-Myc deregulation in dual mTOR 
inhibition, we treated cells with either c-Myc or control 
siRNA for 48 hours and proliferation was performed. 
Silencing the expression of c-Myc resulted in decreased 
proliferation. Moreover treatment with CC214-1 inhibited 
cell proliferation 56% in plasmid alone cells as compared to 
the untreated cells, whereas 83% suppression of proliferation 
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Figure 3: Effect of the dual mTOR kinase inhibitor CC214-1 on eIF4F complex. (A) Effect of CC214-1 on eIF4F complex 
integrity by in vitro cap affinity assay in Jeko and Mino cells. (B) Cap dependent and independent translation was assessed by luciferase 
reporter assay by the use of bicistronic plasmid in the presence of CC214-1. Bars represent mean ± SD from 3 replicates. (C) Survival was 
evaluated in Mino, JVM2, Granta and Jeko cells treated with CC214-1. (D) Effect of CC214-1 on survival inhibition in malignant cells from 
fresh MCL patient was evaluated using annexin V/PI staining and flow cytometry.
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Figure 4: Effect of mTORC1/mTORC2 inhibitor CC214-1 on expression of eIF4E sensitive mRNAs. (A) RT–PCR was 
performed in the CC214-1 treated Jeko and Granta cells using specific primers for cyclin D3, Mcl-1 and c-Myc. GADPH is shown as a 
loading control. The experiment was repeated 3 times. (B) Cyclin D3, Mcl-1 and c-Myc protein expression was assessed by western blotting 
in Jeko cells after treatment with various concentrations of CC214-1. (C) Cyclin D3, Mcl-1 and c-Myc protein expression was assessed in 
eIF4E shRNA stably transfected HEK293 cells in the presence and absence of CC214-1.
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Figure 5: Effect of CC214-1 on polysomal RNA. (A) Polysomal analysis was performed as described in method section in CC214-1 
(4 μM) treated Jeko and Mino cells. Monosomal and polysomal fractions were pooled and Q-PCR was performed for c-Myc (B) cyclin D3 
(C) and Mcl-1 (D). Bars represent mean ± SD from 3 replicates. The Q-PCR data were normalized to GADPH.
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Figure 6: Effect of CC214-1 treatment on eIF4F complex and cell growth in the presence of decreased or increased 
eIF4E. (A, left panel) In vitro cap-affinity assay (mGTP) in HEK293 cells stably transfected by eIF4E shRNA and control shRNA 
plasmids. (A, right panel) In vitro cap-affinity assay was performed in the HEK293 cells transiently transfected by PCDNA3.1 eIF4Ecap mutant 
and eIF4EWT. The experiments were repeated 3 times. (B) HEK293 cells transiently transfected by PCDNA3.1 and eIF4EWT were treated 
with CC214-1 (1 μM) and thymidine incorporation assay (left panel) and flow cytometry (right panel) were performed. Bars represent mean 
± SD from 3 different experiments. (C) Colony forming assay in CC214-1 (1 μM) treated HEK293 cells, stably transfected with eIF4E 
shRNA and control shRNA. Bars represent mean ± SD from 3 replicates. (D) HEK293 cells after transfection by control and c-Myc siRNAs, 
were treated with 1 μM CC214-1 and thymidine incorporation was performed. Bars represent mean ± SD from 3 replicates. The experiment 
was repeated 3 times. The effect of the siRNAs on c-Myc expression was analyzed by western blot.
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was observed in HEK293c-Myc siRNA cells as compared to the 
untreated cells (Figure 6D). Western blotting shows the 
successful knockdown of c-Myc protein (Figure 6D, right).
DISCUSSION
The eIF4F complex, an important downstream 
target of the mTOR pathway, plays a critical role in 
the regulation of cap-dependent translation. Herein we 
show that the active translation initiation eIF4F complex 
(eIF4E-eIF4G-eIF4A) bound to cap is deregulated in 
aggressive lymphoma cells whereas expression of active 
eIF4F assembly in normal B cells is low. In the present 
study we demonstrated that 76% of tumors from newly 
diagnosed DLBCL patients (n = 150) express eIF4E by 
IHC and that this expression predicts shorter EFS. These 
results are consistent with other studies in solid tumors 
that demonstrated inferior patient outcome when the tumor 
cells overexpressed eIF4E.[19] The positive expression of 
4E-BP1[20] and eIF4E[17] in MCL and DLBCL tumors by 
IHC has previously been reported but without relationship 
to patient outcome. We have previously demonstrated in 
a separate cohort of relapsed MCL patients that the 30% 
(9/30) of patients with p4E-BP1+ tumors had a shorter 
progression-free survival when treated with the mTORC1 
inhibitor temsirolimus and rituximab.[21]
In order to address the question whether eIF4E 
availability is necessary for the formation of m7GTP-
eIF4E-eIF4G complex we performed cap-affinity assays 
in transfected cells. Based on our results, the level of 
eIF4E is critical for the formation of the translation 
initiation assembly as its availability is correlated to the 
formation of active eIF4F assembly in a linear form. 
Consistent with previous studies, the eIF4E level did not 
affect global protein translation[22–24], whereas knocking 
down eIF4E decreased the ability of the cells to form 
colonies.[25, 26] Yanagiya et al[24] have attributed the 
observation that global protein translation is not decreased 
despite the strong eIF4E reduction to the fact that hypo-
phosphorylated 4E-BP1 levels are also reduced after 
knocking down eIF4E.
Since a direct inhibitor targeting the eIF4E level 
is currently not available, several studies have aimed at 
targeting eIF4E using indirect approaches.[27, 28] An 
important upstream regulator of the eIF4E pathway is 
mTOR, a serine/threonine protein kinase that functions 
by phosphorylating eIF4E binding proteins (4E-BPs).
[29] The mTOR pathway has been shown to be 
constitutively activated in a high percentage of B-cell 
lymphomas, [11, 30, 31] however, some lymphomas 
develop resistance to mTORC1 inhibition. Indeed, 
multiple clinical trials report modest tumor response 
rates to single-agent mTORC1 inhibitors in many types 
of relapsed NHL, Hodgkin lymphoma and Waldenstrom 
macroglobulinemia.[9] Gupta et al have demonstrated 
before that mTORC1 inhibition with rapamycin resulted 
only in modest antiproliferative effect in aggressive 
lymphoma cells. In the same study, this was attributed 
to resistance due to high expression of mTORC2 
and subsequent Akt and eIF4E phosphorylation.[11] 
Furthermore, Gupta et al have recently provided the 
first demonstration of antiproliferative and proapoptotic 
properties of a dual mTORC1/mTORC2 inhibitor in 
lymphoma through Akt pathway inhibition.[13] In the 
studies reported herein, we sought to understand the 
effect of CC214-1, a next-generation mTORC1/mTORC2 
inhibitor on translation pathway associated with eIF4E. 
We have also investigated the benefits of a potential use 
of the drug in patients. Dual mTOR inhibition targets 
cap-dependent translation by decreasing the association 
between eIF4F assembly and cap, induces apoptosis, 
and inhibits protein expression of c-Myc and cyclin D3 
without much effect on their mRNA expression.
Since transcription was unaffected, a polysome 
analysis in lymphoma cell lines was carried out in 
order to explore the mechanism through which this dual 
mTOR inhibitor suppresses translation. Our data show 
that CC214-1 treatment causes suppression of mRNA 
polysome levels without much effect in monosomal 
mRNA. In addition, CC214-1 inhibits c-Myc, Mcl-1, and 
cyclin D3 translation through suppression of the highly 
translationally active polysomes. These data indicate that 
CC214-1 acts through inhibition of translation initiation 
whereas joining of the ribosomes to the pre-initiation 
complex is unaffected. Of note, we have also observed 
that in some occasions treatment with high concentration 
of drug might decrease total mRNA in monosomes. 
Although our results indicate that CC214-1 acts mainly 
by inhibiting cap-dependent translation, the latter finding 
could be attributed to several factors, as post-treatment cell 
viability was more than 90% in all cases. Wall et al[32] 
have recently reported decreased, rapamycin induced, 
translation of c-Myc in promyelocytes through inhibition 
of translation initiation. Decreased translational efficiency 
of Mcl-1 mRNA after rapamycin treatment has also been 
shown before.[33]
In summary, this study presents information 
regarding alterations in the translation control providing, 
in parallel, a mechanistic basis of targeting cap-dependent 
translation through next generation mTORC1/mTORC2 
inhibitors. The presence of eIF4E expression by IHC 
should be further evaluated in trials of dual mTOR 
inhibitors to learn whether the expression predicts 
response to these agents in lymphoma patients.
METHODS
Cell lines. Mantle cell lymphoma cell (MCL) lines 
Jeko, Mino, Granta and JVM2 were purchased from ATCC 
and grown in Roswell Park Memorial Institute medium 
with 10% fetal bovine serum (FBS). HEK293T cells were 
grown in DMEM medium with 10% FBS.
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Antibodies and reagents. CC214-1, a dual 
mTORC1/mTORC2 inhibitor, was provided by Celgene 
Pharmaceuticals.[34] Phospho-4EB-P1Th37/46, phospho-4E-
BP1Th70, phospho-4E-BP1Ser65, antibodies were purchased 
from the Cell Signaling Technologies (Beverly, MA, USA). 
Antibodies for eIF4E, eIF4G, 4E-BP1, cyclin D3, c-Myc and 
Mcl-1 were also purchased from Cell Signaling Technologies; 
antibody to Actin was purchased from Santa Cruz (Dalas, 
TX, USA). 7-Methyl guanosine triphosphate-Sepharose 
4B (m7GTP) beads were purchased from GE Healthcare 
(Buckinghamshire, HP7 9NA UK).
Patient samples. Tissue microarrays (TMA) were 
constructed using triplicate 0.6-mm cores from paraffin-
embedded DLBCL tissue blocks (n = 142) and included 
10 nonmalignant tonsil controls. The TMA was obtained 
through the University of Iowa/Mayo Lymphoma SPORE. 
All patients provided written consent for use of their 
samples and outcome information and the master protocol 
was approved by the Institutional Review Boards of the 
Mayo Clinic and University of Iowa. Normal B cells were 
isolated using CD19 microbeads (Miltenyi Biotec) from 
peripheral blood mononuclear cells from healthy donors.
Cap affinity assay (m7GTP). Briefly eight to 
ten million cells were washed with ice-cold 1x PBS 
(Phosphate-Buffered Saline) followed by lysis with 
cap binding buffer (20 mM pH7.2 Hepes, 1mM EDTA, 
100 mM KCL, 10% v/v glycerol, 7 mM 2-mercaptoethanol, 
50 mM glycerophosphate, 50 mM Sodium fluoride) using 
four freeze-thaw cycles. 7-Methyl GTP-Sepharose beads 
were added to the lysates and incubated at 4°C for 3 hours 
with rotation. Subsequently, the beads were washed to 
dissolve the protein bound to the beads and western blot was 
performed with specific antibodies.
RNA extraction, cDNA synthesis and RT-PCR. 
RNA extraction, cDNA synthesis, qualitative and quantitative 
RT-PCRs (Q-PCR) were performed as previously described.
[13] The following primers were used for Q-PCR: c-Myc 
forward, 5′- GACGACGAGACCTTCATCAAAAAC-3′, and 
c-Myc reverse, 5′-AGGCCAGCTTCTCTGAGAC-3′; Mcl-1 
forward, 5′- CTGGGATTGAGAGGTTGATGAATG-3′, and 
Mcl-1 reverse, 5′- TGCCCAATCAGAGCCCATTATTTG-3′; 
Cyclin D3 forward, 5′-GGCCCTCTGTGCTACAGA 
TTATACC-3′; Cyclin D3 reverse, 5′-CGCAGGCAGTC 
CACTTCAGTG-3′; Glyceraldehyde-3 phosphate 
dehydrogenase (GADPH) forward, 5′-ATCACCATCTTCC 
AGGAGCG-3′ and GADPH reverse, 5′-CAAATGAGC 
CCCAGCCTTC-3′.
Transient transfection for adherent cells. For 
plasmid transfection, cells were transfected with 5 μg of 
plasmids such as PCDNA3.1, eIF4EWT and eIF4Ecap mutant  
using lipofectamine 2000 reagent (Invitrogen, Grand 
Island, NY, USA) and Opti-MEM medium. For small 
interfering RNA (siRNA) experiments, cells were 
transfected with 50 nM c-Myc siRNA and control siRNA 
using lipofectamine 2000 reagent.
Western blotting. Western blotting was performed 
as described before.[35] Densitometry was performed using 
AlphaImager Software (Alpha Innotech, San Leandro, CA).
Colony formation assay. HEK293T cells were 
treated accordingly and were incubated for 6 days. Cells 
were washed, fixed and stained with a staining solution 
(0.06% coomassie blue, 45% methanol and 10% acetic 
acid). Colonies were counted using colony count program 
on Alphaimager IS-3400 (Alpha Innotech, CA, USA).
3H leucine incorporation assay. 1 X 105 cells 
were treated accordingly for 48 hours. Then cells were 
incubated for 24 h in the presence of 2 μCi/ml leucine. 
10% trichloroacetic acid was added and cells were 
incubated for another 30 min at 4ºC. Cells were lysed with 
0.4N Sodium hydroxide and transferred in triplicates in a 
96 well plate. 3H leucine radioactivity was determined by 
liquid scintillation spectrometer.
Cell survival by annexin V/Propidium iodide. 
Annexin V/PI binding was assayed as described.[11]
Luciferase cap dependent transfection. Jeko cells 
were transfected with luciferase plasmid (pRF) using 
Amaxa Cell Line Nucleofector kit as per manufacturer’s 
instructions. Plasmid pRF was a kind gift from Dr. Gregory 
Goodall.[36] The luciferase assay was performed using a 
dual-luciferase report assay kit (Promega, Madison, WI, 
USA) as per the manufacturer’s instruction.
Thymidine incorporation. 3H-thymidine incorpo-
ration assay as described before.[37]
Polysome analysis. Polysome analysis was performed 
as described earlier with some modifications.[38, 39] 70–90 
million cells were seeded and treated accordingly overnight. 
Cells were treated with 0.1mg/ml cycloheximide (CHX) for 
3min at 37°C and then, cells were collected. All subsequent 
procedures were carried out on ice. Cell lysates were loaded 
on10–50% sucrose density gradients and sedimented 
for 3hrs at 35000 rpm in a Beckman SW40 rotor at 4ºC. 
Gradients were fractionated, and the optical density (OD) 
at 254 nm was counted using density gradient fractionating 
system (Brandel, MD). RNA was precipitated using lithium 
chloride.
Immunohistochemistry (IHC). DLBCL cases 
(n = 132) were classified into GCB or non-GCB 
molecular type based on the Hans algorithm applied to 
paraffin-embedded tumor samples.[40] IHC on tissue 
microarray was performed using eIF4E antibody and IgG 
control as previously described.[41] A 10% cut off was 
chosen for eIF4E positivity. Slides were reviewed by a 
hematopathologist (A.D).
Statistics. Event-free survival (EFS) was defined as 
time from diagnosis to progression, relapse, re-treatment, 
or death due to any cause. Associations between eIF4E 
status and EFS were assessed using Cox proportional 
hazards models and Kaplan Meier curves. The p-value for 
in-vitro data was calculated using the means from 3 different 
experiments (two-tailed unpaired Student’s t test).
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